[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE435219T1 - Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase - Google Patents

Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Info

Publication number
ATE435219T1
ATE435219T1 AT03722769T AT03722769T ATE435219T1 AT E435219 T1 ATE435219 T1 AT E435219T1 AT 03722769 T AT03722769 T AT 03722769T AT 03722769 T AT03722769 T AT 03722769T AT E435219 T1 ATE435219 T1 AT E435219T1
Authority
AT
Austria
Prior art keywords
sulfamides
heteroaryl substituted
gamma secretase
substituted spirocyclic
inhibit gamma
Prior art date
Application number
AT03722769T
Other languages
English (en)
Inventor
Ian James Collins
Laura Catherine Cooper
Timothy Harrison
Linda Elizabeth Keown
Andrew Madin
Mark Peter Ridgill
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209996A external-priority patent/GB0209996D0/en
Priority claimed from GB0223873A external-priority patent/GB0223873D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE435219T1 publication Critical patent/ATE435219T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03722769T 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase ATE435219T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0209996A GB0209996D0 (en) 2002-05-01 2002-05-01 Therapeutic agents
GB0223873A GB0223873D0 (en) 2002-10-14 2002-10-14 Therapeutic agents
US42460802P 2002-11-07 2002-11-07
PCT/GB2003/001763 WO2003093252A1 (en) 2002-05-01 2003-04-24 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Publications (1)

Publication Number Publication Date
ATE435219T1 true ATE435219T1 (de) 2009-07-15

Family

ID=29407321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722769T ATE435219T1 (de) 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Country Status (7)

Country Link
US (3) US7041689B2 (de)
EP (1) EP1503998B1 (de)
AT (1) ATE435219T1 (de)
AU (1) AU2003229932B2 (de)
CA (1) CA2484159C (de)
DE (1) DE60328182D1 (de)
WO (1) WO2003093252A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138400B2 (en) * 2000-11-02 2006-11-21 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
AU2002367147A1 (en) 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
ATE435219T1 (de) * 2002-05-01 2009-07-15 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209995D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
AU2004276050B2 (en) * 2003-09-24 2010-02-25 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Adおよび関連状態の治療のためのピペラジン誘導体
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
MX339144B (es) 2008-06-09 2016-05-13 Univ Muenchen Ludwig Maximilians Nuevas drogas para inhibir la agregacion de proteinas involucradas en enfermedades relacionadas con la agregacion de proteinas y/o enfermedades neurodegenerativas.
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010307198C9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
SG181643A1 (en) * 2009-12-17 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK2606134T3 (da) 2010-08-17 2019-07-22 Sirna Therapeutics Inc RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
EP3970725A1 (de) 2012-09-07 2022-03-23 Massachusetts Eye & Ear Infirmary Ein gamma-sekretase-inhibitor zur behandlung von gehörverlust
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス, インコーポレイテッド 蝸牛シナプス障害を処置する方法
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
TW202430140A (zh) 2022-12-14 2024-08-01 美商默沙東有限責任公司 奧里斯他汀(auristatin)連接子藥物(payload)、醫藥組合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406184A (en) * 1966-05-04 1968-10-15 Du Pont Addition compounds of norbornadienes and quadricyclenes with bis(trifluoromethyl) thioketene and their s-oxides and s-dioxides
US3715362A (en) * 1970-08-17 1973-02-06 Lilly Co Eli Tetracyclic aziridine and method for its preparation
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
WO1998038156A1 (en) 1997-02-27 1998-09-03 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-beta production inhibitors
WO2001070677A1 (en) * 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
US7138400B2 (en) 2000-11-02 2006-11-21 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
ATE435219T1 (de) * 2002-05-01 2009-07-15 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209991D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US7041689B2 (en) 2006-05-09
AU2003229932B2 (en) 2008-12-11
US7282513B2 (en) 2007-10-16
EP1503998B1 (de) 2009-07-01
DE60328182D1 (de) 2009-08-13
CA2484159C (en) 2011-02-22
EP1503998A1 (de) 2005-02-09
WO2003093252A1 (en) 2003-11-13
AU2003229932A1 (en) 2003-11-17
US20060173054A1 (en) 2006-08-03
US20050182109A1 (en) 2005-08-18
CA2484159A1 (en) 2003-11-13
US20080070895A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ATE435219T1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
DE602004007808D1 (de) Neue gamma secretase inhibitoren
DE60112957D1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
ATE299890T1 (de) Inhibitoren von gamma-secretase
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
NO20070606L (no) Inhibitorer av IAP
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
IS7325A (is) alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE452896T1 (de) C3-cyanoepothilonderivate
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
NO20060718L (no) Substituerte tiofoner og deres anvendelse
ATE553077T1 (de) Peptidaseinhibitoren
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties